limiting batch size effects of batch size on risk of contamination with infectious agents
Download
Skip this Video
Download Presentation
Limiting Batch Size: Effects of Batch Size on Risk of Contamination with Infectious Agents

Loading in 2 Seconds...

play fullscreen
1 / 11

Limiting Batch Size: Effects of Batch Size on Risk of ... - PowerPoint PPT Presentation


  • 518 Views
  • Uploaded on

TM Limiting Batch Size: Effects of Batch Size on Risk of Contamination with Infectious Agents Thomas J. Lynch, J.D., Ph.D. Senior Vice President, Regulatory and Quality C L E A R A N T 401 Professional Drive Gaithersburg, MD 20879

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Limiting Batch Size: Effects of Batch Size on Risk of ...' - niveditha


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
limiting batch size effects of batch size on risk of contamination with infectious agents

TM

Limiting Batch Size: Effects of Batch Size on Risk ofContamination with Infectious Agents

Thomas J. Lynch, J.D., Ph.D.Senior Vice President, Regulatory and Quality

C L E A R A N T

401 Professional Drive

Gaithersburg, MD 20879

TSE Advisory CommitteeGaithersburg, MDJune 26, 2002

301-738-2028301-738-9012 (fax) [email protected]

analysis of risk associated with pooling of source materials in the manufacture of biologics
Analysis of Risk Associated withPooling of Source Materials in the Manufacture of Biologics
  • The dissemination of an infectious agent via a pooled product is potentially greater than by single-donor products.
    • The inclusion of one or a few units contaminated with an infectious agent may expose all recipients of product made from a pool to that agent.
  • 1995 analysis done in context of:
    • Pooled Plasma, Solvent/Detergent Treated
    • Later extended to all Plasma Derivatives
pool size in the manufacture of plasma derivatives 1995 analysis
Pool Size in the Manufacture of Plasma Derivatives -- 1995 Analysis
  • Would limiting the size of plasma pools improve the safety of products made from them?
    • If so, what additional safety margins could be achieved at various manufacturing scales?
    • Would limiting the size of manufacturing pools be a prudient safety measure?
  • Should any single donor product be converted to a pooled product?
analysis
Analysis

Simple mathematical models relating:

  • Prevalence of an infectious agent in the donor population;
  • Size of the pools from which plasma derivatives are manufactured;
  • Risk to the recipients.

RISK = Risk of exposing a recipient to material made from a pool that included one or more units derived from infected donors (Risk of Exposure).

= Proportion of a product that is manufactured from infectious pools (Proportionate Risk).

= Probability of including one or more units from infected donors in any single pool (Risk of Contaminating a Pool).

risk of exposure is not risk of infection
Risk of Exposure is not Risk of Infection
  • Risk of Infection may be much less than Risk of Exposure, and is certainly not greater.
  • Transmission of an agent depends on:
    • Infectiousness of the agent.
    • Titer of the agent in the pool.
    • Distribution of the agent during processing.
    • Susceptibility of the recipient population.
  • Risk of Exposure is therefore a worst-case estimate of risk.
slide6

Prevalence of

Infectious Agent

Risk of Including an Infectious Agent in a Plasma Pool Depends on the Prevalence of the Agent and the Size of the Pool

- 1:60,000

100%

- 1:250,000

> 70%

80%

- 1:500,000

20 - 70%

60%

Risk of Contaminating Pool

10 - 20%

- 1:1,000,000

40%

0 - 10%

20%

0%

100

1,000

10,000

100,000

600,000

Pool Size, donors

plasma derivatives vs tissues
RELEVANT

No dilution effect

Suggestions that dilution of infectious agent(s) by pooling may reduce infectivity were discounted

No neutralization by antibodies

Possibility (discounted) of Ab neutralization not likely for tissues

NOT DIRECTLY RELEVANT

Large Pools

Thousands to tens of thousands for plasma derivatives

Tissue pooling smaller

Repeated exposure

Plasma derivatives often administered repeatedly or life-long

Repeated exposure to tissue unusual/limited

Plasma Derivatives vs. Tissues
slide8

Prevalence of

Infectious Agent

Risk of Including an Infectious Agent in a Tissue Pool Depends on the Prevalence of the Agent and the Size of the Pool

1.0%

1:15,000

> 0.4%

0.8%

0.2 - 0.4%

0.6%

Risk of Contaminating Pool

1:60,000

0.4%

0.1 - 0.2%

0.2%

0 - 0.1%

1:250,000

0.0%

1:1,000,000

1

3

10

32

100

Pool Size, donors

slide9

Prevalence of

Infectious Agent

Risk of Including an Infectious Agent in a Tissue Pool Depends on the Prevalence of the Agent and the Size of the Pool

1%

> 0.1%

0.1%

0.01 - 0.1%

1:15,000

0.01%

Risk of Contaminating Pool

0.001 - 0.01%

1:60,000

0.001%

0.0001 - 0.001%

1:250,000

0.0001%

1

3

1:1,000,000

10

32

Pool Size, units

slide10
Risk of Including an Infectious Agent in a Tissue Pool Depends on the Prevalence of the Agent and the Size of the Pool

1%

1:15,000

0.1%

1:60,000

Prevalence of Agent

1:250,000

Risk of Contaminating Pool

0.01%

1:1,000,000

0.001%

0.0001%

1

10

100

Pool Size, donors

conclusions
Conclusions
  • For conversion of a Single Donor Product to a Pooled Product, theoretical risk of exposure increases nearly in proportion to pool size for small or moderately sized pools
  • This risk may be mitigated or offset by benefits imparted by processing:
    • Incorporation of a broadly effective pathogen inactivation method during processing
    • New therapeutic made possible only by manufacturing of pooled source materials
      • Risk:benefit can be analyzed only for known infectious agents
ad